Tt-301

Tt-301

SCHEMBL529969

c1ccc(-c2cc(-c3ccncc3)c(N3CCN(c4ncccn4)CC3)nn2)cc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 3/20 0.60
MAPK14 Q16539 3/20 0.60
SLC6A7 Q99884 5/20 0.51
MAPT P10636 4/20 0.45
LMNA P02545 3/20 0.45
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPK1 P28482 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
TSHR P16473 3/20 0.43
DRD2 P14416 2/20 0.41
DRD4 P21917 2/20 0.41
DRD3 P35462 2/20 0.41
MAPK11 Q15759 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1753099 1.00 CSNK1D (0.60) CSNK1DMAPK14SLC6A7MAPTLMNA
Tt-301 SCHEMBL529453 0.99 CSNK1D (0.59) CSNK1DMAPK14SLC6A7MAPTLMNA
Tt-301 SCHEMBL9998818 0.99 CSNK1D (0.59) CSNK1DMAPK14SLC6A7MAPTLMNA
Tt-301 SCHEMBL300506 0.99 CSNK1D (0.59) CSNK1DMAPK14SLC6A7MAPTLMNA
SCHEMBL29572108 0.95 SLC6A7 (0.56) CSNK1DMAPK14SLC6A7MAPTLMNA
SCHEMBL720267 0.95 SLC6A7 (0.56) CSNK1DMAPK14SLC6A7MAPTLMNA
SCHEMBL14679251 0.87 LMNA (0.56) CSNK1DMAPK14SLC6A7MAPTLMNA
SCHEMBL1753062 0.87 SLC6A7 (0.49) CSNK1DMAPK14SLC6A7MAPTLMNA
SCHEMBL1753146 0.87 CSNK1D (0.46) CSNK1DMAPK14SLC6A7MAPTLMNA
SCHEMBL5005886 0.87 DRD2 (0.49) CSNK1DMAPK14SLC6A7MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195517-A1 TREATMENT OF INTRACRANIAL HEMORRHAGE IMMUNOCHEM THERAPEUTICS, LLC 2025-06-19 US claimed
EP-4482495-A1 TREATMENT OF INTRACRANIAL HEMORRHAGE Immunochem Therapeutics, LLC (US) 2025-01-01 EP claimed
WO-2023163951-A1 TREATMENT OF INTRACRANIAL HEMORRHAGE IMMUNOCHEM THERAPEUTICS, LLC (US) 2023-08-31 WO claimed
CN-114654615-A High-speed mixing control device and control method 康辉新材料科技有限公司 2022-06-24 CN claimed
WO-2012012890-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF ARTHRITIS WARATAH PHARMACEUTICALS INC. (CA) 2012-02-02 WO claimed
WO-2011156900-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS WARATAH PHARMACEUTICALS INC. (CA) 2011-12-22 WO claimed
WO-2011137511-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES WARATAH PHARMACEUTICALS INC. (CA) 2011-11-10 WO claimed
US-20260144674-A1 Apparatus and Methods for Drug Delivery Using Microneedles CLEARSIDE BIOMEDICAL, INC. (US) 2026-05-28 US disclosed
EP-4058037-B1 FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE SPINALCYTE LLC (US) 2026-01-28 EP disclosed
US-20250345206-A1 APPARATUS AND METHODS FOR OCULAR INJECTION CLEARSIDE BIOMEDICAL, INC. (US) 2025-11-13 US disclosed
US-12350261-B2 Methods and devices for the treatment of ocular diseases in human subjects CLEARSIDE BIOMEDICAL, INC. (US) 2025-07-08 US disclosed
US-20250195517-A1 TREATMENT OF INTRACRANIAL HEMORRHAGE IMMUNOCHEM THERAPEUTICS, LLC 2025-06-19 US disclosed
US-20250186253-A1 DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY CLEARSIDE BIOMEDICAL, INC. (US) 2025-06-12 US disclosed
US-20080318899-A1 Pyridazine Compounds, Compositions and Methods UNIVERSITE DE STRASBOURG (FR) 2008-12-25 US disclosed
WO-2007130383-A2 COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES NORTHWESTERN UNIVERSITY (US) 2007-11-15 WO disclosed
WO-2007127475-A2 PYRIDAZINES FOR DEMYELINATING DISEASES AND NEUROPATHIC PAIN NORTHWESTERN UNIVERSITY (US) 2007-11-08 WO disclosed
WO-2007127375-A2 FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES NORTHWESTERN UNIVERSITY (US) 2007-11-08 WO disclosed
WO-2007127474-A2 COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS NORTHWESTERN UNIVERSITY (US) 2007-11-08 WO disclosed
EP-1812408-A2 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS Northwestern University (US) 2007-08-01 EP disclosed
WO-2006050389-A2 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS NORTHWESTERN UNIVERSITY (US) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144674-A1 Apparatus and Methods for Drug Delivery Using Microneedles PROKR2, SLC10A2, GLP1R CSNK1D 1998/4885MAPK14 735/4885SLC6A7 412/4885
US-20080318899-A1 Pyridazine Compounds, Compositions and Methods APP, PSEN1, PSEN2 CSNK1D 1547/4885MAPK14 126/4885SLC6A7 3890/4885
US-20250195517-A1 TREATMENT OF INTRACRANIAL HEMORRHAGE FABP7, PROC, PLG CSNK1D 2450/4885MAPK14 4681/4885SLC6A7 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.